Capricor Therapeutics Inc (CAPR) Upgraded by Zacks Investment Research to “Buy”
Capricor Therapeutics Inc (OTCMKTS:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday. The brokerage currently has a $1.25 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 14.68% from the company’s current price.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
CAPR has been the topic of several other reports. ValuEngine cut Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. HC Wainwright set a $2.00 price objective on Capricor Therapeutics and gave the company a “buy” rating in a research note on Monday. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $2.15 price objective on shares of Capricor Therapeutics in a research note on Saturday, July 22nd. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $4.35.
Shares of Capricor Therapeutics (OTCMKTS:CAPR) traded up 2.83% during midday trading on Wednesday, reaching $1.09. The company’s stock had a trading volume of 457,204 shares. The stock’s 50-day moving average is $0.98 and its 200-day moving average is $1.99. Capricor Therapeutics has a one year low of $0.63 and a one year high of $4.09. The company’s market capitalization is $24.63 million.
Capricor Therapeutics (OTCMKTS:CAPR) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $1 million for the quarter, compared to analyst estimates of $1.10 million. On average, equities analysts expect that Capricor Therapeutics will post ($0.74) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Capricor Therapeutics Inc (CAPR) Upgraded by Zacks Investment Research to “Buy”” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/capricor-therapeutics-inc-capr-upgraded-by-zacks-investment-research-to-buy/1496430.html.
A hedge fund recently raised its stake in Capricor Therapeutics stock. LLBH Private Wealth Management LLC increased its stake in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 27.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 184,591 shares of the biotechnology company’s stock after buying an additional 40,000 shares during the period. LLBH Private Wealth Management LLC owned 0.82% of Capricor Therapeutics worth $153,000 at the end of the most recent reporting period.
About Capricor Therapeutics
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.